Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA4 | P22748 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.34 |
| ▸ | GLP1R | P43220 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ENO1 | P06733 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12655854 | 1.00 | MEN1 (0.40) | MEN1KMT2ACES2CA2NCF1 | |
| SCHEMBL16426613 | 1.00 | MEN1 (0.40) | MEN1KMT2ACES2CA2NCF1 | |
| SCHEMBL12850137 | 1.00 | MEN1 (0.40) | MEN1KMT2ACES2CA2NCF1 | |
| SCHEMBL12666252 | 0.97 | MEN1 (0.40) | MEN1KMT2ACES2CA2NCF1 | |
| SCHEMBL12666247 | 0.97 | MEN1 (0.40) | MEN1KMT2ACES2CA2NCF1 | |
| SCHEMBL12666251 | 0.97 | MEN1 (0.40) | MEN1KMT2ACES2CA2NCF1 | |
| SCHEMBL13649533 | 0.97 | MEN1 (0.40) | MEN1KMT2ACES2CA2NCF1 | |
| SCHEMBL24040332 | 0.91 | MEN1 (0.41) | MEN1KMT2ACA2NCF1CA12 | |
| SCHEMBL17029409 | 0.90 | CA2 (0.38) | MEN1KMT2ACES2CA2CA12 | |
| SCHEMBL26376485 | 0.89 | CES2 (0.44) | MEN1KMT2ACES2GLP1RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186608-B2 | Solid phase synthesis of acylated peptides | BACHEM HOLDING AG (CH) | 2021-11-30 | — | — | US | disclosed |
| EP-2932981-B1 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK AS (DK) | 2021-06-16 | — | — | EP | disclosed |
| US-20210009631-A1 | SOLID PHASE SYNTHESIS OF ACYLATED PEPTIDES | BACHEM HOLDING AG (CH) | 2021-01-14 | — | — | US | disclosed |
| EP-3110840-B1 | AN A22K, DESB27, B29R, DES B30, AT EPSILON POSITION OF LYSINE 22 ACYLATED HUMAN INSULIN ANALOGUE | NOVO NORDISK AS (DK) | 2020-10-21 | — | — | EP | disclosed |
| WO-2017127827-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATION | TUFTS MEDICAL CENTER (US) | 2017-07-27 | — | — | WO | disclosed |
| US-9708383-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2017-07-18 | — | — | US | disclosed |
| EP-2190873-B1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK AS (DK) | 2015-07-22 | — | — | EP | disclosed |
| EP-2178912-B1 | INSULIN ANALOGUES WITH AN ACYL AND AKLYLENE GLYCOL MOIETY | NOVO NORDISK AS (DK) | 2015-07-08 | — | — | EP | disclosed |
| US-20140371148-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | ASTRAZENECA PHARMACEUTICALS LP | 2014-12-18 | — | — | US | disclosed |
| EP-2190460-B1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | NOVO NORDISK AS (DK) | 2014-12-17 | — | — | EP | disclosed |
| US-8759295-B2 | Peptide-peptidase inhibitor conjugates and methods of using same | AMYLIN PHARMACEUTICALS, LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130244931-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2013-09-19 | — | — | US | disclosed |
| US-8263739-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20100292172-A1 | Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009030774-A1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009631-A1 | SOLID PHASE SYNTHESIS OF ACYLATED PEPTIDES | QPCT, DNPEP, PTMS | MEN1 1488/4885KMT2A 2448/4885CES2 3462/4885 |
| US-20100292172-A1 | Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same | DNPEP, PEPD, VIP | MEN1 998/4885KMT2A 2386/4885CES2 253/4885 |
| US-11186608-B2 | Solid phase synthesis of acylated peptides | QPCT, DNPEP, PTMS | MEN1 1488/4885KMT2A 2448/4885CES2 3462/4885 |
| US-20140371148-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | DNPEP, PEPD, VIP | MEN1 998/4885KMT2A 2386/4885CES2 253/4885 |
| US-20130244931-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | MEN1 680/4885KMT2A 4238/4885CES2 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.